Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973788 | 1.00 | TRPV1 (0.38) | TRPV1TSHRPPARGPPARAFFAR1 | |
| SCHEMBL19973785 | 1.00 | TRPV1 (0.38) | TRPV1TSHRPPARGPPARAFFAR1 | |
| SCHEMBL22553027 | 1.00 | TRPV1 (0.38) | TRPV1TSHRPPARGPPARAFFAR1 | |
| SCHEMBL103467 | 0.91 | — | — | |
| SCHEMBL8018136 | 0.91 | — | — | |
| SCHEMBL453672 | 0.91 | — | — | |
| SCHEMBL9652371 | 0.88 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL9652378 | 0.88 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL11220605 | 0.88 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL8567129 | 0.85 | TRPV1 (0.46) | TRPV1PPARGPPARAFFAR1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12031130-B2 | Composition for modifying target gene | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-09 | — | — | US | disclosed |
| US-11993570-B2 | Cationic lipids | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-28 | — | — | US | disclosed |
| EP-3733641-B1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-111511713-B | Cationic lipid | 武田药品工业株式会社 | 2024-01-02 | — | — | CN | disclosed |
| CN-111527204-B | Composition for target gene modification | 国立大学法人京都大学 | 2023-09-01 | — | — | CN | disclosed |
| US-20230257338-A1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20210371854-A1 | COMPOSITION FOR MODIFYING TARGET GENE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3733844-A1 | COMPOSITION FOR MODIFYING TARGET GENE | Kyoto University (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733641-A1 | CATIONIC LIPIDS | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20200331841-A1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993570-B2 | Cationic lipids | ELOVL5, LPCAT3, ELOVL3 | TRPV1 1432/4885TSHR 4055/4885PPARG 2275/4885 |
| US-20210371854-A1 | COMPOSITION FOR MODIFYING TARGET GENE | NSUN2, NSUN3, RNASE1 | TRPV1 4572/4885TSHR 3411/4885PPARG 3442/4885 |
| US-12031130-B2 | Composition for modifying target gene | NSUN2, NSUN3, RNASE1 | TRPV1 4572/4885TSHR 3411/4885PPARG 3442/4885 |
| US-20230257338-A1 | CATIONIC LIPIDS | ELOVL5, LPCAT3, ELOVL3 | TRPV1 1432/4885TSHR 4055/4885PPARG 2275/4885 |
| US-20200331841-A1 | CATIONIC LIPIDS | ELOVL5, LPCAT3, ELOVL3 | TRPV1 1432/4885TSHR 4055/4885PPARG 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.